Your browser doesn't support javascript.
loading
Vaccine value profile for norovirus.
Armah, George; Lopman, Ben A; Vinjé, Jan; O'Ryan, Miguel; Lanata, Claudio F; Groome, Michelle; Ovitt, Jared; Marshall, Caroline; Sajewski, Elizabeth; Riddle, Mark S.
Afiliação
  • Armah G; Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Ghana.
  • Lopman BA; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
  • Vinjé J; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • O'Ryan M; Microbiology and Mycology Program, Faculty of Medicine, University of Chile and Instituto de Sistemas Complejos de Ingenierìa (ISCI), Santiago, Chile.
  • Lanata CF; Instituto de Investigación Nutricional, Lima, Peru.
  • Groome M; National Institute for Communicable Diseases, National Health Laboratory Services, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Ovitt J; Office of Medical Research, University of Nevada, Reno School of Medicine, Reno, Nevada, USA.
  • Marshall C; World Health Organization, Geneva, Switzerland.
  • Sajewski E; Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA, USA.
  • Riddle MS; Office of Medical Research, University of Nevada, Reno School of Medicine, Reno, Nevada, USA. Electronic address: markriddlemd@gmail.com.
Vaccine ; 41 Suppl 2: S134-S152, 2023 11 03.
Article em En | MEDLINE | ID: mdl-37951692
Norovirus is attributed to nearly 1 out of every 5 episodes of diarrheal disease globally and is estimated to cause approximately 200,000 deaths annually worldwide, with 70,000 or more among children in developing countries. Noroviruses remain a leading cause of sporadic disease and outbreaks of acute gastroenteritis even in industrialized settings, highlighting that improved hygiene and sanitation alone may not be fully effective in controlling norovirus. Strengths in global progress towards a Norovirus vaccine include a diverse though not deep pipeline which includes multiple approaches, including some with proven technology platforms (e.g., VLP-based HPV vaccines). However, several gaps in knowledge persist, including a fulsome mechanistic understanding of how the virus attaches to human host cells, internalizes, and induces disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Infecções por Caliciviridae / Norovirus / Gastroenterite Limite: Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vacinas Virais / Infecções por Caliciviridae / Norovirus / Gastroenterite Limite: Child / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article